RxDoctor Payments Data

David Friedman

Nephrology · Boston, MANPI 1194763482

Payments from drug & device makers

What this record shows

This record is dominated by royalties or licence payments: $19,750,000 of the $19,786,647 with a category attached, or 99.8%. Vertex accounts for 100.0% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2021 at $18,755,428 and has fallen 100.0% since, to $3,704 in 2025. Among nephrology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$19,786,647in general payments, 2019–2025

Across 35 payments — averaging $565,333 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vertex$19.8M
  • Sanofi$7K
  • Genentech USA, Inc.$61
$4,673,381in research payments, 2019–2025

Across 6 payments — averaging $778,897 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Vertex$4.7M

What the payments were for

  • Royalty or licence$19,750,000100%
  • Consulting fees$35,6790%
  • Travel & lodging$6060%
  • Food & beverage$3620%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Vertex29$19,779,451
Sanofi5$7,134
Genentech USA, Inc.1$61

How this compares

$19,786,647 in reported general payments places this provider in the 95th percentile of 339 nephrology providers in Massachusetts.

See all nephrology providers in Massachusetts →

Other nephrology in Boston

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →